RICHMOND, Calif., Jun. 25 (Korea Bizwire) — Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that the latest Ekso Bionics robotic gait therapy software upgrade, first available in Europe, will be revealed at the 28th Annual Meeting of the German Speaking Medical Society for Paraplegia (DMGP) in Kassel, Germany. The four-day congress attracts medical specialists and paraplegia experts from all over the world to address the challenges in bringing high quality, comprehensive and successful treatment of paraplegic patients.
Ekso GT™ with SmartAssist™ features include: the next generation of adaptive assistance software, enabling a greater number of interactive steps; PreGait, a suite of early mobilization activities for pre-ambulatory patients preparing for gait therapy; and FreeGait, an advanced mode for patients progressing to community ambulation.
As previously announced at Rehab Week, this new Ekso GT package will also support integration of Functional Electric Stimulation (FES) from Hasomed for research use, providing the opportunity for facilities operating under research protocols to partner with Ekso to advance research on complimentary therapies.
Ekso GT with new SmartAssist software supports a broader spectrum of patients who are more actively engaged in their rehabilitation. The new SmartAssist programming provides patients with an unparalleled ability to vary the step path based on their own effort. High step variability has been associated with enhanced locomotor rehabilitation1.
“Ekso GT with SmartAssist software is developed to expand the applications for use within clinics. We believe the addition of pre-gait exercises will facilitate earlier mobility for some patients who could not have otherwise been mobile and our new FreeGait advanced mode can help patients at a late stage in the recovery process ambulate more freely while progressing to community ambulation,” says Darrell Musick, PT and VP of Clinical Services.
The Company’s commercial plan anticipates an initial launch of the SmartAssist robotic gait therapy software package for Ekso GT in Europe by the end of 2015. The SmartAssist software is not yet available in the United States.
1Lewek MD1, Cruz TH, Moore JL, Roth HR, Dhaher YY, Hornby TG.
Allowing intralimb kinematic variability during locomotor training poststroke improves kinematic consistency: a subgroup analysis from a randomized clinical trial. Phys Ther. 2009 Aug;89(8):829-39. doi: 10.2522/ptj.20080180. Epub 2009 Jun 11.
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are wearable, battery-powered robots that are strapped over the user’s clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics’ lead product, Ekso GT™, is a wearable robotic exoskeleton that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso Bionics is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury, and other neurological conditions affecting gait.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company’s first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com
Any statements contained in this press release that do not describe historical facts may constitute forward?looking statements. Forward?looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward?looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward?looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward?looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Director of Marketing Communications
Phone: 510-984-1761 x317
Chad Rubin, Senior Vice President
Source: Ekso Bionics via GLOBE NEWSWIRE